arginine and Cystadenocarcinoma, Serous

arginine has been researched along with Cystadenocarcinoma, Serous in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Crook, T; Hiller, L; Kimberley, C; Koensgen, D; Mustea, A; Nicholson, LJ; Schmid, P; Sehouli, J; Smith, PR; Szlosarek, PW	1

Other Studies

1 other study(ies) available for arginine and Cystadenocarcinoma, Serous

Article	Year
Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. International journal of cancer, 2009, Sep-15, Volume: 125, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Arginine; Argininosuccinate Synthase; Carboplatin; Cell Death; Cisplatin; Cystadenocarcinoma, Serous; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Immunoblotting; Middle Aged; Ovarian Neoplasms; Paclitaxel; Promoter Regions, Genetic; Survival Rate; Tumor Cells, Cultured	2009

Article

Year

Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.

International journal of cancer, 2009, Sep-15, Volume: 125, Issue:6

Topics: Antineoplastic Combined Chemotherapy Protocols; Arginine; Argininosuccinate Synthase; Carboplatin; Cell Death; Cisplatin; Cystadenocarcinoma, Serous; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Immunoblotting; Middle Aged; Ovarian Neoplasms; Paclitaxel; Promoter Regions, Genetic; Survival Rate; Tumor Cells, Cultured

2009